Ribociclib 400mg Clinical Trials

3 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Kisqali

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

Yale University1
Relay Therapeutics, Inc.1
Nagoya City University1

Indications

Breast Cancer3
Cancer3
HER2-negative Breast Cancer2
PIK3CA Mutation1
Unresectable Solid Tumor1

Other1 trial

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2

Tucson, Arizona1 trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

The University of Arizona Cancer Center

Phase 1

New Haven, Connecticut1 trial

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Yale University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.